1. Home
  2. DYAI vs CASI Comparison

DYAI vs CASI Comparison

Compare DYAI & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYAI
  • CASI
  • Stock Information
  • Founded
  • DYAI 1979
  • CASI 1991
  • Country
  • DYAI United States
  • CASI China
  • Employees
  • DYAI N/A
  • CASI N/A
  • Industry
  • DYAI Biotechnology: Biological Products (No Diagnostic Substances)
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • DYAI Health Care
  • CASI Health Care
  • Exchange
  • DYAI Nasdaq
  • CASI Nasdaq
  • Market Cap
  • DYAI 35.5M
  • CASI 29.7M
  • IPO Year
  • DYAI 2004
  • CASI 1996
  • Fundamental
  • Price
  • DYAI $1.04
  • CASI $1.91
  • Analyst Decision
  • DYAI Strong Buy
  • CASI Strong Buy
  • Analyst Count
  • DYAI 1
  • CASI 1
  • Target Price
  • DYAI $6.00
  • CASI $4.00
  • AVG Volume (30 Days)
  • DYAI 38.3K
  • CASI 7.5K
  • Earning Date
  • DYAI 05-14-2025
  • CASI 05-27-2025
  • Dividend Yield
  • DYAI N/A
  • CASI N/A
  • EPS Growth
  • DYAI N/A
  • CASI N/A
  • EPS
  • DYAI N/A
  • CASI N/A
  • Revenue
  • DYAI $3,495,389.00
  • CASI $28,537,000.00
  • Revenue This Year
  • DYAI $117.40
  • CASI N/A
  • Revenue Next Year
  • DYAI N/A
  • CASI N/A
  • P/E Ratio
  • DYAI N/A
  • CASI N/A
  • Revenue Growth
  • DYAI 20.58
  • CASI N/A
  • 52 Week Low
  • DYAI $0.93
  • CASI $1.64
  • 52 Week High
  • DYAI $2.67
  • CASI $7.67
  • Technical
  • Relative Strength Index (RSI)
  • DYAI 28.85
  • CASI 46.41
  • Support Level
  • DYAI $1.05
  • CASI $1.81
  • Resistance Level
  • DYAI $1.13
  • CASI $1.95
  • Average True Range (ATR)
  • DYAI 0.07
  • CASI 0.10
  • MACD
  • DYAI -0.01
  • CASI 0.00
  • Stochastic Oscillator
  • DYAI 14.29
  • CASI 61.36

About DYAI Dyadic International Inc.

Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: